Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 9:13:1308460.
doi: 10.3389/fonc.2023.1308460. eCollection 2023.

The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors

Giuseppe Bronte  1   2 , Alessia Belloni  2 , Luana Calabrò  3   4 , Lucio Crinò  5
Affiliations

The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors

Giuseppe Bronte et al. Front Oncol. .
No abstract available

Keywords: allosteric inhibitor; non-small cell lung cancer; osimertinib; resistance; tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

LCa has served as consultant or advisor to Bristol-Myers Squibb, Merck Sharp and Dohme, and has received compensated educational activities from Bristol Myers Squibb, Astrazeneca, and Sanofi. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Future scenario for treating patients who developed resistance during or after osimertinib according to post-progression molecular characterization. EGFR, Epidermal Growth Factor Receptor; MET, MET Proto-Oncogene, Receptor Tyrosine Kinase; HER2, Human Epidermal Growth Factor Receptor 2; HER3, Human Epidermal Growth Factor Receptor 3; 4G, fourth generation; Dato-DXd, Datopotamab Deruxtecan; HER3-DXd, Patritumab Deruxtecan; Teliso-V, Telisotuzumab Vedotin; T-DXd, Trastuzumab Deruxtecan; SCLC, small cell lung cancer; Sq-NSCLC, squamous non-small cell lung cancer.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. . The effect of advances in lung-cancer treatment on population mortality. N Engl J Med (2020) 383:640–9. doi: 10.1056/NEJMoa1916623 - DOI - PMC - PubMed
    1. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. . Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol (2023) 34:358–76. doi: 10.1016/j.annonc.2022.12.013 - DOI - PubMed
    1. Hendriks LE, Kerr KM, Menis J, Mok S, Nestle U, Passaro A, et al. . EGC. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol (2023) 34:339–57. doi: 10.1016/j.annonc.2022.12.009 - DOI - PubMed
    1. Lee CK, Davies L, Wu Y-L, Mitsudomi T, Inoue A, Rosell R, et al. . Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival. J Natl Cancer Inst (2017) 109(6). doi: 10.1093/jnci/djw279 - DOI - PubMed
    1. Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al. . Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med (2017) 376:629–40. doi: 10.1056/NEJMoa1612674 - DOI - PMC - PubMed

LinkOut - more resources